unknown
Stage
1
Investors
About
Claris Bio develops novel biologic therapies for corneal diseases, focusing on restoring corneal integrity with their lead topical ocular biologic dHGF for Limbal Stem Cell Deficiency (LSCD).
Explore Claris Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.